Neuro-Behavioral Clinical Research, Inc

Summary

Neuro-Behavioral Clinical Research, Inc is a medical facility located in Canton, Ohio. This center is recognized for care of Major Depressive Disorder, Depression, Alzheimer's Disease, Schizophrenia, Dementia and other specialties. Neuro-Behavioral Clinical Research, Inc is involved with conducting 95 clinical trials across 66 conditions. There are 2 research doctors associated with this hospital, such as Shishuka Malhotra, MD and Shiskuka Malhotra, MD.

Top PIs

Clinical Trials running at Neuro-Behavioral Clinical Research, Inc

Alzheimer's Disease

Depression

Memory Loss

Mania

Bipolar disorder

Sickle Cell Disease

Thalassemia

Cognitive Impairment

Schizophrenia

Adolescent Health

Biomarker Database

for Alzheimer's Disease

Bio-Hermes-002 is a 120-day cross-sectional study that will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine the primary objective. Digital biomarkers and blood-based biomarkers will be tested to determine whether a meaningful relationship exists between biomarkers alone or in combination with tau or amyloid brain pathology identified through PET images.

Recruiting

1 award

N/A

10 criteria

ONO-2020

for Alzheimer's Disease

This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess safety, tolerability, pharmacokinetics, and efficacy of ONO-2020 in participants with mild to moderate Alzheimer's disease (AD). This study aims to determine whether administering ONO-2020, an epigenetic regulator, may improve cognitive functions like memory and cognition in individuals with Alzheimer's disease dementia.

Recruiting

0 awards

Phase 2

2 criteria

MK-2214

for Alzheimer's Disease

Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer's disease (AD). AD is a type of dementia that can cause loss of memory, communication (such as speech), and decision-making skills. It can limit a person's ability to do daily tasks. MK-2214 is a study treatment designed to slow down AD. The goals of the study are to learn: * If MK-2214 slows the spread of tau in the brain compared to placebo. Tau is a protein that accumulates in AD \& damages brain cells. A placebo looks like the study treatment but has no study treatment in it. Using a placebo helps researchers better understand the effects of a study treatment. * About the safety of MK-2214 and if people tolerate it

Recruiting

0 awards

Phase 2

1 criteria